Skip to content

Cullinan Therapeutics, Inc.

CGEM· NasdaqCore metricsCIK 1789972

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -10.06%
Market cap
$661.54M
64.92M shares
Filings
471
$0.00
FY 2022−100.0% FY22 yoy
-$49.39M
Q3 2026N/M FY25 yoy
-$52.60M
Q3 2026N/M FY25 yoy
-$127.35M
Q3 2026derivedN/M FY25 yoy
-$0.69
Q3 2024N/M FY23 yoy
$88.26M
Q3 2026+6.4% FY25 yoy
$661.54M
—
—
2.4×
-26.57%
—

FY2025 figures · derived

Price

$10.19+30.47%+$2.38past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00FY 2022
$18.94M0FY 2020FY 2021FY 2022
PeriodEndedValueKindSource trail
FY 20222022-12-31$0reported
FY 20212021-12-31$18,943,000reported
FY 20202020-12-31$0reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2020—$6.57M$6.57M—29.83M sh——

Biological products, except diagnostic substances

Cullinan Therapeutics, Inc. is the 55th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Cullinan Therapeutics, Inc. · CIK 1789972 · Engraved from SEC EDGAR